A Phase 2 interventional study of Apo-levocarb in Major Depressive Disorder, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by University of British Columbia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Depressive Disorder, Major by University of British Columbia — 5 open to participants now, 7 under way, none of them phase 3. Depressive Disorder, Major · University of British Columbia.
Among the 16 studies in Depressive Disorder, Major by University of British Columbia, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2, and was the 15th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 16 studies in Depressive Disorder, Major by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 19–55 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 19–65
University of British Columbia · Sites in Canada
Ages 18–65
University of British Columbia · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 72 across the 15 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
2 of the studies in Depressive Disorder, Major by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05423275University of British ColumbiaLight and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study | 2026-12 |
| NCT04999553University of British ColumbiaLeft vs. Right Non-Inferiority Trial | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Depressive Disorder, Major by University of British Columbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background
Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired. For example, they might not be able to walk or process information as quickly, and they might have problems with their working memory.
Psychomotor slowing in LLD might be the result of a problem with the way a person's body produces or responds to the neurotransmitter dopamine. The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect psychomotor slowing in LLD.
Methods
In this study, participants are adults aged 60 years or older with moderate to severe major depression. Participants undergo the "L-DOPA challenge"-a 2-week period where they receive a dose of L-DOPA once a day for the first week and a dose of L-DOPA twice a day for the second week. Before and after a participant completes the L-DOPA challenge, the study team assesses their depressive symptoms and psychomotor function. After the L-DOPA challenge, if a participant still shows signs of moderate or severe depression, they receive an antidepressant for 12 weeks.
Aims
The first aim of this study is to test the feasibility of the L-DOPA challenge-that is, whether most of the 50 participants recruited for this study will complete the L-DOPA challenge. For example, participants might have to withdraw if they can't make the daily visits to the research site to receive their L-DOPA medication, if they can't tolerate the medication's side effects, or if their depressive symptoms get significantly worse. Our hypothesis is that 80% of the participants will complete the L-DOPA challenge.
The second aim of the study is to see if L-DOPA affects participants' depressive symptoms, processing speed, and working memory. Our hypothesis is that L-DOPA response, measured as an improvement in gait speed, is associated with a decrease in depressive symptoms and an increase in processing speed and working memory.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered a levodopa-carbidopa challenge, at a dosage of 150mg/37.5mg once daily for one week, followed by twice daily for one week. Psychomotor speed will be assessed before and after the challenge.
Drug: Apo-levocarb
As above.
L-DOPA challenge completion rate
Number of participants who complete the 2-week challenge of receiving L-DOPA and post-challenge assessments
Time frame: 6 months
Depressive symptoms
Change in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale, after the L-DOPA challenge and after treatment for depression
Time frame: At 2, 3, 7, and 15 weeks from baseline
Gait speed
Change in gait speed in response to L-DOPA, as measured by time to complete the 4-metre walk test.
Time frame: At baseline and 2 weeks from baseline
Psychomotor speed
Changes in psychomotor speed in response to L-DOPA, as measured by the clinician-rated CORE instrument
Time frame: At baseline and 2 weeks from baseline
Processing speed
Change in processing speed, as measured by the NIH Toolbox Cognitive Battery: Pattern Comparison tool, after the L-DOPA challenge and after treatment for depression
Time frame: At 2 and 15 weeks from baseline
Working memory
Change in working memory, as measured by the NIH Toolbox Cognitive Battery: List Sorting tool, after the L-DOPA challenge and after treatment for depression
Time frame: At 2 and 15 weeks from baseline
Side effects related to L-DOPA
Incidence, frequency, and severity of side effects following L-DOPA administration, related to the cardiovascular, respiratory, musculoskeletal, genitourinary, skin, and central nervous systems, as recorded on an Adverse Effects Monitoring Form
Time frame: At 2 weeks from baseline
Started Aug 2024 (actual). Primary completion is estimated for May 2026, 21 months after the start.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 21 months is below that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →